Publication | Closed Access

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Neurobiology Of DiseaseOphthalmologyNeurological DisorderPlacebo-controlled Phase 2/3NeurologyMedicineOptic NerveNeuroimmunology